Caplin Point Laboratories Ltd (CAPLIPOINT)
₹2,467.10
Mkt cap
₹18,753 Cr
P/E ratio
29.20
P/B
5.23
Div yield
0.24%
ROE
20.60%
ROCE
24.60%
EPS (TTM)
₹84.49
Book value
₹472
52W range
1,505–2,672
Sector
Healthcare
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations. [1]
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−7.65% from high₹2,467
₹1,505+63.95% from low₹2,672
Current
₹2,467.10
Prev close
₹2,483.00
Day
−0.64%
Price performance
1D
−0.64%
1W
−6.87%
1M
−1.57%
3M
+43.48%
6M
+38.40%
1Y
+16.95%
YTD
+33.44%
Financials
FRevenue, profit & margin
P/E ratio
29.2×
CAPLIPOINT is 14% below the sector median of 34.0×
CAPLIPOINT29.2×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 389 | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | |
| Expenses | 265 | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | |
| Operating Profit | 124 | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | |
| OPM % | 32% | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% | |
| Other Income | 11 | 12 | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 11 | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | |
| Profit before tax | 124 | 127 | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 | |
| Tax % | 18% | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | |
| Net Profit | 101 | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | |
| EPS in Rs | 13.45 | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 | 21.56 | 22.38 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.03% · closed higher next day 19 of last 39
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 8 Aug '23 | 10 Nov '23 | 9 Feb '24 | 17 May '24 | 7 Aug '24◦ | 8 Nov '24 | 7 Feb '25◦ | 15 May '25◦ | 7 Aug '25◦ | 5 Nov '25◦ | 5 Feb '26 | 14 May '26 |
| Earnings day | +11.12% | +8.36% | −0.77% | −1.65% | −6.27% | −5.18% | −4.38% | +0.47% | +2.56% | +0.46% | −0.29% | +9.88% |
| +1 day | +12.49% | +14.06% | +2.88% | −3.58% | −5.07% | −5.16% | −8.15% | +8.02% | +2.40% | −3.14% | −4.39% | +8.52% |
| +5 days | +18.53% | +14.75% | +9.20% | −4.43% | +0.30% | −6.27% | −10.38% | +9.61% | +4.54% | −2.95% | −9.04% | +10.00% |
| +15 days | +20.23% | +12.97% | +6.05% | +0.13% | +20.51% | +8.99% | −18.37% | +4.63% | +3.36% | −4.34% | −9.47% | +10.39% |
| +30 days | +11.99% | +25.81% | −12.76% | +6.49% | +22.70% | +12.98% | −10.22% | +4.17% | +9.49% | −4.39% | −15.99% | +38.88% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Interim Dividend - Rs 4 Per Share | 4.00 | 29 May '26 | 30 May '26 |
Shareholding
Sas of Jun 202670.57%Promoter
Promoters70.57%
FIIs5.76%0.39
DIIs2.49%0.35
Public21.19%0.05
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Caplin Point Lab | ₹2,467.10 | 29.24 | 18,753 | 0.24% | 173 | +19.32% | 600 | +19.45% | 24.63% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2011bse
Concall transcripts49
TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024
Announcements5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 11 Jul - Submitted Regulation 74(5) depository certificate for quarter ended June 30, 2026.Closure of Trading Window 27 JunAnnouncement under Regulation 30 (LODR)-Newspaper Publication 22 Jun - Newspaper advertisement for transfer of Unclaimed dividend and shares to IEPFCompliances-Reg.24(A)-Annual Secretarial Compliance 29 May - Caplin Point filed FY26 secretarial compliance report; postal ballot voting results delayed, Rs.10,000 plus GST fine waived.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 May - Caplin Point will attend TRINITY INDIA 2026 investor conference on May 28, 2026 in Mumbai.